GlassScriptPhysician profile
Reema Patel
NPI 1912768748
$2,092.12
in general payments reported to CMS, 2019-2025
17 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $898 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.85 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $366.97 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $256.95 | 2025 | Auvelity |
| Abbvie INC. | $249.85 | 2024-2025 | |
| Novo Nordisk INC | $212.92 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $195.66 | 2024-2025 | Tavneos, Repatha, Otezla |
| Abbott Laboratories | $173.98 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $140.70 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $139.16 | 2025 | Kisunla, Jardiance |
| Glaxosmithkline, LLC. | $113.61 | 2024 | Shingrix |
| Astellas Pharma US INC | $67.14 | 2025 | Veozah |
| Pfizer INC. | $62.52 | 2024 | |
| Verity Pharmaceuticals INC. | $24.82 | 2025 | Tlando |
| Exact Sciences Corporation | $21.63 | 2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $19.77 | 2025 | Licart, Tirosint, Flector |
| Azurity Pharmaceuticals, INC. | $17.27 | 2024 | Horizant |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2024 | Trulance, Xifaxan |
| Currax Pharmaceuticals LLC | $14.29 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reema Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.